Posted by Michael Wonder on 23 Jul 2024
FDA approves Samsung Bioepis’ Epysqli (eculizumab-aagh) as a biosimilar to Soliris (eculizumab)
22 July 2024 - Epysqli is approved for the treatment of patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome.
Samsung Bioepis announced today that the US FDA has approved the biologics license application for Epysqli (eculizumab-aagh) as a biosimilar to Soliris (eculizumab).
